Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX) completed enrollment in its U.S. Phase 2b clinical trial of the 18F‑labeled imaging agent RAD 101, which targets fatty acid synthase in patients with recurrent brain metastases. The final patient was dosed on April 16 2026, and the company announced the milestone on April 23 2026. The completion of enrollment marks the last step before the company can begin the pivotal Phase 3 study and is a key de‑risking event that brings the diagnostic platform closer to regulatory review and potential partnership or acquisition opportunities.
The company also reported interim Phase 0/1 data for its therapeutic RAD 202, a 177Lu‑labeled nanobody targeting HER2. At the American Association for Cancer Research Annual Meeting on April 20 2026, the data showed encouraging tumor uptake and a favorable safety profile at the lowest dose level. The Data and Safety Monitoring Committee approved escalation to the third cohort at 130 mCi, a decision that supports continued dose‑escalation and positions the program for the next dose‑level study.
In addition, Radiopharm Theranostics initiated two first‑in‑human trials: RV‑01, a B7H3‑targeted therapy launched through a Radiopharm Ventures collaboration, and RAD 402, a prostate‑cancer agent. Both trials began in February and March 2026, respectively, expanding the company’s therapeutic pipeline into new disease indications and demonstrating the platform’s versatility.
Management emphasized the significance of these milestones. "Dosing the final patient in our most advanced diagnostic program represents an important milestone for Radiopharm and underscores the continued momentum of our radiopharmaceutical pipeline," said CEO Riccardo Canevari. He added, "We entered 2026 with strong momentum and continue to execute across our differentiated therapeutics and diagnostics pipeline. The Phase 2b interim results for RAD 101, demonstrating 90% concordance with MRI in recurrent brain metastases, further validate the potential of our imaging platform and strengthen our confidence as we prepare for the next stages of development." Dr. Dimitris Voliotis, Chief Medical Officer, noted, "In a heavily pre‑treated patient population with significant unmet need, 177Lu‑RAD202 demonstrated encouraging tumor uptake and a favorable safety profile at the lowest dose level. Importantly, the observed dosimetry supports continued dose escalation, which was recently approved by the Data Safety and Monitoring Committee (DSMC) to advance to the third cohort at 130 mCi dosing." Canevari also highlighted the new trials, stating, "Importantly, the initiation of two additional Phase 1 trials—RV‑01 through our Radiopharm Ventures collaboration and RAD 402 in advanced prostate cancer—reflects the growing productivity of our platform and our disciplined approach to pipeline expansion. With multiple clinical milestones ahead, we are well positioned to build long‑term value as we advance innovative radiopharmaceuticals for patients with high unmet needs."
Financially, the company reported $19.2 million in cash as of April 23 2026, down from $34.5 million at the end of the prior quarter. Net operating cash outflows of $14.9 million in the most recent quarter indicate a short cash runway, underscoring the importance of the clinical milestones for attracting additional funding or partnership opportunities.
Analysts responded positively to the announcement, noting that the enrollment completion and interim data de‑risk the diagnostic and therapeutic programs. The milestones are viewed as a strong signal of the company’s execution capability and its potential to secure future collaborations or acquisitions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.